The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Oncolytic Virotherapies
In article number 2206948, Ying Wu, Ning Li, Funan Liu, and co‐workers provide a more advanced approach to cancer immunotherapy, i.e. the oncolytic virotherapy. Oncolytic viruses selectively replicate in tumor cells and exert antitumor effects through direct oncolysis and inducting immune responses, where tumor antigens from the lysing cells enhance antitumor immunity.
With advances in cancer biology and an ever‐deepening understanding of molecular virology, oncolytic virus (OV)‐driven therapies have developed rapidly and become a promising alternative to traditional cancer therapies. In recent years, satisfactory results for oncolytic virus therapy (OVT) are achieved at both the cellular and organismal levels, and efforts are being increasingly directed toward...